ProCE Banner Activity

CE / CME

Managing Major Depression: Can We Do Better?

Multimedia

This on-demand webcast reviews current management strategies for major depression, evidence supporting therapy augmentation with atypical antipsychotic agents, and individualizing treatment plans for patient- and disease state–specific characteristics.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Social Workers: 1.00 ASWB ACE CE Credit

Released: December 23, 2022

Expiration: December 22, 2023

No longer available for credit.

Share

Faculty

Manish K. Jha

Manish K. Jha, MD

Associate Professor of Psychiatry
O'Donnell Clinical Neuroscience Scholar
Center for Depression Research and Clinical Care
UT Southwestern Medical Center
Dallas, Texas

Vladimir Maletic

Vladimir Maletic, MD, MS

Clinical Professor of Psychiatry
University of South Carolina
Greenville, South Carolina

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This program is supported by an educational grant from:

AbbVie Inc.

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists, social workers, physician associates (physician assistants/physician associates), and psychologists engaged in the care of patients with psychiatric disorders.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illnesses.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the unmet needs in major depression as they relate to current treatment strategies
  • Assess evidence supporting the use of atypical antipsychotics as augmentation therapy in major depression
  • Construct evidence-based patient treatment plans based on patient- and disease state–specific characteristics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Manish K. Jha, MD

Associate Professor of Psychiatry
O'Donnell Clinical Neuroscience Scholar
Center for Depression Research and Clinical Care
UT Southwestern Medical Center
Dallas, Texas

Manish K. Jha, MDconsultant/advisor/speaker: Boehringer Ingelheim, Eleusis Therapeutics, Guidepoint Global, HC Wainwright & Co., IQVIA, Janssen Global Services, Janssen Research and Development, Vicore Pharma, Medscape/WebMD, Worldwide Clinical Trials, Psychiatry Clinics of North America, Psychiatry and Behavioral Health Learning Network; researcher: Janssen Research and Development, Naviator/Supernus, Neurocrine.

Vladimir Maletic, MD, MS

Clinical Professor of Psychiatry
University of South Carolina
Greenville, South Carolina

Vladimir Maletic, MD: consultant/advisor/speaker: AbbVie, Alfasigma, Alkermes, Intra-Cellular, Janssen, Lundbeck, Otsuka, Sage, Supernus.

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Alkermes, Akilli, Axsome, Boehringer Ingelheim, Emalex, Idorsida, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine, NLS-1 Pharma AG, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Amber Hoberg, PMHNP, and Amanda Zimmerman, PA-C as noted below:

Amber Hoberg, PMHNP, consultant: Acadia, Avanir, BioXcel, Intracellular Therapies, Neurocrine, Teva.

Amanda Zimmerman, PA-C, researcher: Biodelivery Sciences International.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 23, 2022, through December 22, 2023:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-314-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until December 22, 2023. PAs should only claim credit commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity offers 1 continuing education credit for psychologists.

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 clinical continuing education credit.